These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

587 related items for PubMed ID: 18339135

  • 1. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes.
    Eid AJ, Arthurs SK, Deziel PJ, Wilhelm MP, Razonable RR.
    Clin Transplant; 2008; 22(2):162-70. PubMed ID: 18339135
    [Abstract] [Full Text] [Related]

  • 2. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients.
    Boivin G, Goyette N, Gilbert C, Roberts N, Macey K, Paya C, Pescovitz MD, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Covington E.
    J Infect Dis; 2004 May 01; 189(9):1615-8. PubMed ID: 15116297
    [Abstract] [Full Text] [Related]

  • 3. Delayed-onset primary cytomegalovirus disease after liver transplantation.
    Arthurs SK, Eid AJ, Pedersen RA, Dierkhising RA, Kremers WK, Patel R, Razonable RR.
    Liver Transpl; 2007 Dec 01; 13(12):1703-9. PubMed ID: 18044717
    [Abstract] [Full Text] [Related]

  • 4. Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis.
    Martin M, Goyette N, Ives J, Boivin G.
    J Clin Virol; 2010 Apr 01; 47(4):321-4. PubMed ID: 20138805
    [Abstract] [Full Text] [Related]

  • 5. Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus.
    Allice T, Busca A, Locatelli F, Falda M, Pittaluga F, Ghisetti V.
    J Antimicrob Chemother; 2009 Mar 01; 63(3):600-8. PubMed ID: 19147520
    [Abstract] [Full Text] [Related]

  • 6. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance.
    van der Beek MT, Berger SP, Vossen AC, van der Blij-de Brouwer CS, Press RR, de Fijter JW, Claas EC, Kroes AC.
    Transplantation; 2010 Feb 15; 89(3):320-6. PubMed ID: 20145523
    [Abstract] [Full Text] [Related]

  • 7. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
    Jain A, Orloff M, Kashyap R, Lansing K, Betts R, Mohanka R, Menegus M, Ryan C, Bozorgzadeh A.
    Transplant Proc; 2005 Sep 15; 37(7):3182-6. PubMed ID: 16213344
    [Abstract] [Full Text] [Related]

  • 8. Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection.
    Boutolleau D, Deback C, Bressollette-Bodin C, Varnous S, Dhedin N, Barrou B, Vernant JP, Gandjbakhch I, Imbert-Marcille BM, Agut H.
    Antiviral Res; 2009 Feb 15; 81(2):174-9. PubMed ID: 19063923
    [Abstract] [Full Text] [Related]

  • 9. Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients.
    Cervera C, Pineda M, Linares L, Marcos MA, Esteva C, Antón A, Cofán F, Ricart MJ, Navasa M, Pérez-Villa F, Pumarola T, Moreno A.
    Transplant Proc; 2007 Sep 15; 39(7):2228-30. PubMed ID: 17889146
    [Abstract] [Full Text] [Related]

  • 10. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M, VIPP Study Group.
    Transplantation; 2012 Jan 15; 93(1):61-8. PubMed ID: 22094954
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis.
    Wiita AP, Roubinian N, Khan Y, Chin-Hong PV, Singer JP, Golden JA, Miller S.
    Transpl Infect Dis; 2012 Jun 15; 14(3):248-58. PubMed ID: 22385394
    [Abstract] [Full Text] [Related]

  • 13. Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study.
    Young PG, Rubin J, Angarone M, Flaherty J, Penugonda S, Stosor V, Ison MG.
    Transpl Infect Dis; 2016 Jun 15; 18(3):390-5. PubMed ID: 27037651
    [Abstract] [Full Text] [Related]

  • 14. Prospective long-term study on primary CMV infections in adult liver transplant (D+/R-) patients after valganciclovir prophylaxis.
    Lautenschlager I, Loginov R, Mäkisalo H, Höckerstedt K.
    J Clin Virol; 2015 Oct 15; 71():73-5. PubMed ID: 26318605
    [Abstract] [Full Text] [Related]

  • 15. New developments in the management of cytomegalovirus infection after solid organ transplantation.
    Eid AJ, Razonable RR.
    Drugs; 2010 May 28; 70(8):965-81. PubMed ID: 20481654
    [Abstract] [Full Text] [Related]

  • 16. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis.
    Mitsani D, Nguyen MH, Kwak EJ, Silveira FP, Vadnerkar A, Pilewski J, Crespo M, Toyoda Y, Bermudez C, Clancy CJ.
    J Heart Lung Transplant; 2010 Sep 28; 29(9):1014-20. PubMed ID: 20598582
    [Abstract] [Full Text] [Related]

  • 17. Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis.
    Boivin G, Goyette N, Gilbert C, Covington E.
    J Med Virol; 2005 Nov 28; 77(3):425-9. PubMed ID: 16173018
    [Abstract] [Full Text] [Related]

  • 18. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients.
    Myhre HA, Haug Dorenberg D, Kristiansen KI, Rollag H, Leivestad T, Asberg A, Hartmann A.
    Transplantation; 2011 Jul 27; 92(2):217-23. PubMed ID: 21685829
    [Abstract] [Full Text] [Related]

  • 19. Prolonged Low-Dose Prophylaxis With Valganciclovir in Cytomegalovirus-Negative Recipients of Kidney Transplants From Cytomegalovirus-Positive Donors Allows Seroconversion and Prevents Cytomegalovirus Disease.
    Halleck F, Khadzhynov D, Schrezenmeier E, Lehner L, Budde K, Staeck O.
    Transplant Proc; 2017 Dec 27; 49(10):2280-2284. PubMed ID: 29198661
    [Abstract] [Full Text] [Related]

  • 20. Cytomegalovirus infection after liver transplantation: current concepts and challenges.
    Razonable RR.
    World J Gastroenterol; 2008 Aug 21; 14(31):4849-60. PubMed ID: 18756591
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.